WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-09 15:38:43
[post_modified_gmt] => 2024-08-09 19:38:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3747
[post_author] => 1
[post_date] => 2021-04-07 19:08:28
[post_date_gmt] => 2021-04-07 19:08:28
[post_content] =>
Companies with an active NIH SBIR or STTR Phase I or Phase I Fast-Track award (grant or contract) within the past two years are eligible to receive a Technical and Business Assistance (TABA) Program Needs Assessment Report*
The TABA Needs Assessment Report provides a third party, unbiased assessment of your progress in 10 technical and business areas that are critical to success in the competitive healthcare marketplace including Target Market Attractiveness (Need/Size), Ability to Address Market Need, Regulatory Path and more. Learn more: https://sbir.nih.gov/support-for-awardees/taba-needs-assessment
*For companies with multiple awards, only one project will be considered for the program. Small businesses that have received TABA funding within their Phase I award are not eligible to participate.
[post_title] => SBIR/ATTR Awardees: Open Eligibility for Needs Assessment Report
[post_excerpt] => Companies with an active NIH SBIR or STTR Phase I or Phase I Fast-Track award (grant or contract) within the past two years are eligible to receive a Technical and Business Assistance (TABA) Program Needs Assessment Report.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sbir-attr-awardees-open-eligibility-for-needs-assessment-report
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:12:02
[post_modified_gmt] => 2021-09-20 16:12:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3747
[menu_order] => 49
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2275
[post_author] => 3
[post_date] => 2016-06-22 14:40:28
[post_date_gmt] => 2016-06-22 14:40:28
[post_content] =>
The Center for Biotechnology team recently ventured out to San Francisco for BIO’s annual International Convention. Through the support of Empire State Development and the Long Island Bioscience Hub, the Center for Biotechnology was able to support six Long Island emerging biotech companies to attend the meeting: Alpha-1 Biologics Corporation, Codagenix, Inc., DepYMed, Inc., iCell Gene Therapeutics, PhD Skin Care LLC and Vela Therapeutics. These companies were joined in the New York Pavilion by more than two dozen other companies and entities representing New York State.
Long Island and New York City regional companies Alpha-1 Biologics, Vela Therapeutics, Intrommune Therapeutics, PainQX, Serendipity Biotech, ENB Therapeutics, and QuickSilver Biosystems all were recipients of grants from Empire State Development and NewYorkBio which also assisted their participation in the event. These companies were tapped to present in the New York Pavilion along with six other companies from upstate New York.
Envisagenics, ENB Therapeutics, PainQx, QuickSilver and Abcombi BioSciences, all New York State Companies, were invited to participate in the BIO 2016 “Start-Up Stadium” which provide start-up companies with the opportunity to pitch to key members of the investment community, venture philanthropy groups, and BIO attendees. The participating investors provided live feedback and judged the sessions.
In addition, six Long Island Bioscience Hub faculty members were invited to participate in the meeting for the first time. These NIH-REACH program supported faculty attended with the goal to learn more about the commercialization process, how it applies to their translational research, and to engage in the partnering process and meet with potential strategic contacts. Center staff met with over 40 strategic partners over the course of the meeting and follow up is underway.
[post_title] => BIO 2016
[post_excerpt] => The Center for Biotechnology team recently attended the BIO International Convention in San Francisco and supported the participation of emerging companies and faculty entrepreneurs in the event.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bio-international-convention-2016
[to_ping] =>
[pinged] =>
[post_modified] => 2016-07-14 13:50:46
[post_modified_gmt] => 2016-07-14 13:50:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2275
[menu_order] => 175
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2510
[post_author] => 4
[post_date] => 2016-11-30 19:37:58
[post_date_gmt] => 2016-11-30 19:37:58
[post_content] => Codagenix, Inc. has entered into an exclusive licensing agreement with Stony Brook University, through the Research Foundation for the State of New York, to commercialize a platform technology to develop a pipeline of live attenuated vaccines against viral infections in people and animals. The technology relies on software to re-design the genomes of potentially harmful viruses to make them safe and effective vaccines. The technology stems from research in the laboratory of Eckard Wimmer, PhD, Distinguished Professor in the Department of Molecular Genetics & Microbiology. The lead indication for vaccine development generated is a vaccine against Seasonal Influenza slated for Phase I human clinical trials in 2017.
Dr. Wimmer, along with Steffen Mueller, PhD, Codagenix President and Chief Science Officer, and J. Robert Coleman, PhD, Codagenix Chief Operating officer, worked as colleagues for years in Dr. Wimmer’s laboratory examining and experimenting with the genes of viruses. By collaborating with Stony Brook scientists Bruce Futcher, PhD, in the Department of Molecular Genetics & Microbiology, and Steven Skienna, PhD, in the Department of Computer Science, they discovered a way using gene manipulation and computer algorithms to “re-code” the genes of viruses. This re-coding process makes viruses extremely weak and thus ideal candidates as ultra-low dose attenuated vaccines.
The licensing agreement enables Codgenix to develop and potentially market next generation vaccines using software-based gene design and whole viral synthesis to create low-dose, attenuated virus vaccines. The company expects to use this design to first test its vaccine against influenza; however, there are plans for human testing of their Zika and other vaccine candidates. Codagenix is also in partnership with a large agricultural company to make vaccines using the technology for companion and agricultural animals.
The technology has been shown to be effective against numerous viruses including ZIka, Dengue, and RSV all of which are in preclinical testing. The development of this pipeline of vaccines can be seen in numerous scientific papers since 2008, including a paper in Science, PNAS, National Biotechnology and most recently in 2015 in MBIo.
Read Stony Brook University's full press release here.
[post_title] => Codagenix Inks Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => codagenix-inks-exclusive-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2017-03-15 13:49:05
[post_modified_gmt] => 2017-03-15 13:49:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2510
[menu_order] => 157
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-09 15:38:43
[post_modified_gmt] => 2024-08-09 19:38:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 260
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)